In an 86‑year‑old female nursing‑home resident with dementia, severe anxiety, depression, and agitation who is taking memantine 5 mg at bedtime, should the memantine be continued at the current dose, increased, or discontinued?

Memantine Management in an 86-Year-Old Nursing Home Resident with Dementia and Neuropsychiatric Symptoms

Consider discontinuing memantine in this patient given her severe or end-stage dementia presentation in a nursing home setting, particularly if she has been on treatment for >12 months without clear benefit, or if her agitation and anxiety have not meaningfully improved with memantine. 1

Clinical Decision Framework

Step 1: Assess Criteria for Discontinuation

The 2020 Canadian Consensus Conference provides clear criteria for memantine discontinuation in patients with AD, PDD, DLB, or VD who have been treated for >12 months 1:

Discontinuation should be considered if ANY of the following apply:

• Clinically meaningful worsening over the past 6 months in cognition, function, or global assessment (excluding delirium, acute medical illness, or recent relocation as causes)
• No clinically meaningful benefit observed at any time during treatment (no improvement, stabilization, or decreased rate of decline)
• Severe or end-stage dementia (dependence in most basic ADLs, inability to respond to environment, or limited life expectancy)
• Intolerable side effects (confusion, dizziness, falls)
• Poor medication adherence precluding safe use or effectiveness assessment

Step 2: Evaluate Current Clinical Status

Critical assessment points for this patient:

• Dementia severity: As a nursing home resident at age 86, assess if she has severe/end-stage dementia with dependence in basic ADLs and limited environmental responsiveness
• Treatment duration: Determine if she has been on memantine >12 months
• Benefit assessment: Has memantine provided any stabilization of cognition, function, or neuropsychiatric symptoms since initiation?
• Neuropsychiatric symptoms: Her severe anxiety, depression, and agitation may warrant special consideration

Step 3: Consider the Neuropsychiatric Symptom Context

Important nuance: The guidelines specifically state that cognitive enhancers (including memantine) should continue if the patient has had a clinically meaningful reduction in neuropsychiatric symptoms (e.g., psychosis) with the medication, even if there is evidence of cognitive and functional decline 1. This is a 2B recommendation with 96% consensus.

However, the evidence for memantine's efficacy in agitation is mixed:

• A 2012 RCT found no significant benefit for clinically significant agitation in moderate-to-severe AD 2
• Post-hoc analyses suggest possible benefit for agitation/aggression 3
• An open-label study showed reduced nursing burden with memantine for agitation 4

Step 4: Dosing Considerations

The current dose of 5 mg QHS is subtherapeutic. The FDA label clearly states 5:

• Starting dose: 5 mg once daily
• Target therapeutic dose: 20 mg/day (10 mg twice daily)
• Dose increases: 5 mg increments weekly
• Exception: Severe renal impairment (CrCl 5-29 mL/min) requires target dose of 5 mg twice daily

If continuing memantine, the dose must be titrated to 20 mg/day to achieve therapeutic benefit, unless severe renal impairment is present.

Recommended Clinical Algorithm

If Memantine Has Been Used >12 Months:

1. Assess for discontinuation criteria (see Step 1 above)
2. If ANY criterion is met AND neuropsychiatric symptoms have NOT meaningfully improved with memantine: Proceed with gradual discontinuation
3. If neuropsychiatric symptoms DID improve with memantine: Continue treatment even if cognitive/functional decline is present

If Continuing Memantine:

1. Verify renal function (calculate CrCl using Cockcroft-Gault)
2. If CrCl >29 mL/min: Titrate to 20 mg/day (increase by 5 mg weekly: 5→10→15→20 mg/day)
3. If CrCl 5-29 mL/min: Titrate to 5 mg twice daily (10 mg/day total)
4. Monitor for side effects: confusion, dizziness, falls 5

If Discontinuing Memantine:

Follow the deprescribing protocol 1:

• Reduce dose by 50% every 4 weeks until reaching initial starting dose (5 mg/day)
• After 4 weeks at 5 mg/day, discontinue completely
• Monitor closely for clinically meaningful worsening of cognition, function, or neuropsychiatric symptoms
• Reinitiate treatment if worsening appears related to cessation

Critical Pitfalls to Avoid

1. Do not maintain subtherapeutic dosing: 5 mg QHS provides no proven benefit; either titrate to therapeutic dose or discontinue
2. Do not abruptly discontinue: Gradual tapering is essential 1
3. Do not ignore neuropsychiatric benefit: If memantine has helped agitation/anxiety, continue despite cognitive decline 1
4. Do not overlook renal function: Severe renal impairment requires dose adjustment 5
5. Do not continue indefinitely without reassessment: Nursing home residents with severe dementia and limited life expectancy may not benefit from continued treatment 1

Safety Considerations

Memantine-based combinations carry distinct safety signals 6:

• When combined with antipsychotics: increased risk of falls, hip fracture (ROR 15.84), psychiatric and nervous system disorders
• Common adverse effects: dizziness, headache, confusion, constipation 5
• Discontinuation rates due to adverse events: 10.1% (similar to placebo 11.5%) 5

Given this patient's severe anxiety, depression, and agitation, carefully evaluate whether memantine is contributing to or alleviating these symptoms before making a decision.